Dr. Mark Lowenthal joined NIST in 2007 following a post-doctoral position at the University of Colorado Health Sciences Center and a research fellowship at the National Cancer Institute (NCI/NIH). Mark received a Ph.D. from the University of Maryland in analytical/physical chemistry and a B.S. from James Madison University.
His research activities at NIST focus on the measurement of proteins, metabolites, amino acids, and sugars in all types of biomaterials. Current aims include the development of a glycan-based Standard Reference Material, measurement assays for hemoglobin A1c, and creating tools for predicting protein glycosylation using evolutionary sequence conservation.
Mark has developed new methods for quantification of troponin I in serum - an important protein marker of cardiac muscle injury - using immunoaffinity techniques and mass spectrometry. Quantification of clinically-relevant biomolecules has led to the production and certification of several NIST Standard Reference Materials. Other research applications include mass spectrometry-related measurements of proteins associated with neurodegenerative disorders, characterization of antibody function on nanoparticles, and detection of microbial virulence.
Mark has co-authored 33 peer-reviewed publications and two book chapters. He is a member of the IFCC CSF working group, GBSC, and the NIH GlycoSIG working group.